Table 2.

Phase III trials testing solanezumab.

Study Design and Duration	Study Population	Cognitive Primary Endpoint	CSF or Plasma Aβ	Amyloid PET	Volumetric MRI
Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 1, 2) 80 weeks [54]	Mild to moderate AD	ADAS-Cog11 and ADCS-ADL Significant small effects for ADCS-ADL only in EXPEDITION 2 Significant small effects in a secondary analysis on the pooled mild AD-population [55]	Significant increase in plasma and CSF	No significant effects	No significant effects
Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 3) 76 weeks [56]	Mild AD	ADAS-Cog11 No significant effects	Significant increase in plasma and CSF	No significant effects	No significant effects
Phase III, randomised, double-blind, placebo-controlled (A4) 240 weeks [58]	Preclinical AD	PACC No significant effects	ND	Smaller increase vs. placebo	No significant effects
Phase II/III, randomised, double-blind, placebo-controlled (DIAN-TU) 208 weeks [72]	Dominantly inherited AD	DIAN-MCE No significant effects	Significant increase in CSF	No significant effects	No significant effects

ND, not determined.